New Insights for Infection Mechanism and Potential Targets of COVID-19: Three Chinese Patent Medicines and Three Chinese Medicine Formulas As Promising Therapeutic Approaches

Overview

Journal Chin Herb Med

Publisher Elsevier

Date 2023 May 23

PMID 37220535

Authors

Kexin Jia

Yijie Li

Tiegang Liu

Xiaohong Gu

Xiaojiaoyang Li

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high pathogenicity and infectiousness has become a sudden and lethal pandemic worldwide. Currently, there is no accepted specific drug for COVID-19 treatment. Therefore, it is extremely urgent to clarify the pathogenic mechanism and develop effective therapies for patients with COVID-19. According to several reliable reports from China, traditional Chinese medicine (TCM), especially for three Chinese patent medicines and three Chinese medicine formulas, has been demonstrated to effectively alleviate the symptoms of COVID-19 either used alone or in combination with Western medicines. In this review, we systematically summarized and analyzed the pathogenesis of COVID-19, the detailed clinical practice, active ingredients investigation, network pharmacology prediction and underlying mechanism verification of three Chinese patent medicines and three Chinese medicine formulas in the COVID-19 combat. Additionally, we summarized some promising and high-frequency drugs of these prescriptions and discussed their regulatory mechanism, which provides guidance for the development of new drugs against COVID-19. Collectively, by addressing critical challenges, for example, unclear targets and complicated active ingredients of these medicines and formulas, we believe that TCM will represent promising and efficient strategies for curing COVID-19 and related pandemics.

Citing Articles

Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis.

Bi C, He J, Yuan Y, Che S, Cui T, Ning L J Glob Health. 2025; 15:04056.

PMID: 40019163 PMC: 11869518. DOI: 10.7189/jogh.15.04056.

Genome-wide identification of the bHLH gene family in and their relationship with baicalin biosynthesis under drought stress.

Sun Y, Wang B, Zhang L, Zheng X, Xu P, Zhang M Front Plant Sci. 2025; 15:1506805.

PMID: 39931340 PMC: 11807981. DOI: 10.3389/fpls.2024.1506805.

Inhibitory Efficacy of Main Components of on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II.

Lin C, Chang H, Lin M, Yang X, Lee C, Lin C Int J Mol Sci. 2024; 25(5).

PMID: 38474182 PMC: 10932139. DOI: 10.3390/ijms25052935.

Exploring the chemical components of Kuanchang-Shu granule and its protective effects of postoperative ileus in rats by regulating AKT/HSP90AA1/eNOS pathway.

Duan W, Cai M, Ma Q, Huang P, Zhang J, Wei T Chin Med. 2024; 19(1):29.

PMID: 38383512 PMC: 10880223. DOI: 10.1186/s13020-024-00892-3.

Anemoside B4 inhibits SARS-CoV-2 replication and .

Xiao M, Luo R, Liang Q, Jiang H, Liu Y, Xu G Chin Herb Med. 2024; 16(1):106-112.

PMID: 38375049 PMC: 10874757. DOI: 10.1016/j.chmed.2023.09.005.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Middleton E, He X, Denorme F, Campbell R, Ng D, Salvatore S . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020; 136(10):1169-1179. PMC: 7472714. DOI: 10.1182/blood.2020007008. View

Zhang Z, Morris-Natschke S, Cheng Y, Lee K, Li R . Development of anti-influenza agents from natural products. Med Res Rev. 2020; 40(6):2290-2338. DOI: 10.1002/med.21707. View

Baez-Santos Y, Barraza S, Wilson M, Agius M, Mielech A, Davis N . X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem. 2014; 57(6):2393-412. PMC: 3983375. DOI: 10.1021/jm401712t. View

Erfinanda L, Ravindran K, Kohse F, Gallo K, Preissner R, Walther T . Oestrogen-mediated upregulation of the Mas receptor contributes to sex differences in acute lung injury and lung vascular barrier regulation. Eur Respir J. 2020; 57(1). DOI: 10.1183/13993003.00921-2020. View

Yang R, Liu H, Bai C, Wang Y, Zhang X, Guo R . Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study. Pharmacol Res. 2020; 157:104820. PMC: 7194979. DOI: 10.1016/j.phrs.2020.104820. View

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

Xiong W, Wang G, Du J, Ai W . Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial. Integr Med Res. 2020; 9(3):100489. PMC: 7452296. DOI: 10.1016/j.imr.2020.100489. View

Otto S, Day T, Arino J, Colijn C, Dushoff J, Li M . The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. Curr Biol. 2021; 31(14):R918-R929. PMC: 8220957. DOI: 10.1016/j.cub.2021.06.049. View

10.

Xia Q, Xun Y, Lu J, Lu Y, Yang Y, Zhou P . Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell Prolif. 2020; 53(12):e12949. PMC: 7705900. DOI: 10.1111/cpr.12949. View

11.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

12.

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

13.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

14.

Huang S, Liu Y, Zhang Y, Zhang R, Zhu C, Fan L . Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner. Signal Transduct Target Ther. 2020; 5(1):266. PMC: 7662024. DOI: 10.1038/s41392-020-00353-x. View

15.

Liu Z, Li X, Gou C, Li L, Luo X, Zhang C . Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J Tradit Chin Med. 2020; 40(3):467-472. DOI: 10.19852/j.cnki.jtcm.2020.03.016. View

16.

Zheng S, Baak J, Li S, Xiao W, Ren H, Yang H . Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW. Phytomedicine. 2020; 79:153336. PMC: 7474845. DOI: 10.1016/j.phymed.2020.153336. View

17.

Noris M, Benigni A, Remuzzi G . The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020; 98(2):314-322. PMC: 7246017. DOI: 10.1016/j.kint.2020.05.013. View

18.

An X, Xu X, Xiao M, Min X, Lyu Y, Tian J . Efficacy of Jinhua Qinggan Granules Combined With Western Medicine in the Treatment of Confirmed and Suspected COVID-19: A Randomized Controlled Trial. Front Med (Lausanne). 2021; 8:728055. PMC: 8545827. DOI: 10.3389/fmed.2021.728055. View

19.

Gando S, Wada T . Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. Front Immunol. 2021; 12:649122. PMC: 8226122. DOI: 10.3389/fimmu.2021.649122. View

20.

Song Y, Yao C, Yao Y, Han H, Zhao X, Yu K . XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med. 2019; 47(9):e735-e743. PMC: 6727951. DOI: 10.1097/CCM.0000000000003842. View